SeraCare Life Sciences (SRLS) agrees to be acquired for $80.8M by PE firm Linden Capital Partners. The $4/share deal reflects a premium of 19% to Friday's closing price. SRLS, which supplies diagnostic control products for HIV, plasma-derived reagents and contract research services, had said last year it was exploring strategic alternatives.
SeraCare Life Sciences (SRLS) says it will explore and evaluate potential strategic alternatives to enhance shareholder value, including a sale or other transaction, but there is no set timetable for making a decision. SRLS +3.3% premarket. (PR)